AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 11 min read$USNA

Fleming John Turman sold $44K of USNA

Fleming John Turman sold 2,450 shares of USANA HEALTH SCIENCES INC (USNA) at $17.93 on 2026-06-01.

Original reporting
SEC EDGAR · Fleming John Turman
Published Jun 1, 2026, 8:36 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 1, 2026, 9:01 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$USNA
Neutral
medium confidence
Mentioned
$USNA
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$USNANeutralLow
01

Why it matters

This is a disclosed ownership change (open-market sale) that can marginally affect sentiment but does not introduce new operational or financial information.

02

Market read

Traders may monitor USNA for any clustering of insider activity, but the filing alone is unlikely to drive a sustained repricing.

03

What to watch

Absence of a stated 10b5-1 plan does not prove bearish intent; traders should check for prior insider patterns and any concurrent buys/sales in the same window.

Relevance 6/10Novelty 6/10Timing: SEC Form 4 filed today (2026-06-01) after-hours/late session disclosure

Background

The article is an SEC Form 4 insider transaction disclosure for USANA Health Sciences director Fleming John Turman.

Company-level read

Ticker impact

$USNANeutralMedium confidence
Context

USANA director Fleming John Turman sold 2,450 shares in an open-market transaction disclosed via SEC Form 4 today.

Expected impact

Likely limited, short-lived impact unless follow-on selling or broader negative news emerges.

Evidence & confidence

The filing provides a concrete datapoint (sale price/value and post-transaction holdings) but no new fundamentals, guidance, or event beyond ownership change.

Market effects

Sector

Minimal—single-company insider transaction without sector-wide catalyst.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

The sale may be routine liquidity/portfolio rebalancing rather than a negative view, especially since the filing does not explicitly tie to performance or a corporate event.

Key entities

  • issuer
    USANA HEALTH SCIENCES INC

    Subject of the insider transaction disclosure; director sold shares on 2026-06-01.

  • insider
    Fleming John Turman

    Director who sold 2,450 shares at $17.93/share; holdings after sale: 4,230 shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

USNA insider trading history →

Related articles

AUG 12
$USNAMedAI 8/10

USANA (USNA) Q2 2026 Earnings Call Transcript

USANA (USNA) held its Q2 2026 earnings call. Management said Core Nutritional was stable, with Mainland China showing renewed strength. The company recorded a preliminary $29 million noncash goodwill impairment and $9 million income tax expense on a $19 million pretax loss. USANA ended the quarter with $169 million cash, zero debt, and $20 million free cash flow, and lowered its fiscal 2026 outlook due to HYA DTC marketing and Rise net sales.

yahoo.com6 min
AUG 11
$USNAMedAI 8/10

USANA Health Sciences Q2 Earnings Call Highlights

USANA Health Sciences (NYSE:USNA) reported Q2 updates including a $29 million preliminary non-cash goodwill impairment tied to its Hiya reporting unit and $9 million income tax expense on a $19 million pre-tax loss. Management cited about $30 million to $40 million top-line pressure and $4 million to $5 million margin pressure, plus a Rise packaging disruption. USANA ended with $169 million cash and no debt.

yahoo.com6 min
AUG 9
$USNAHighAI 9/10

Why Usana Health Sciences Stock Plummeted This Week

Usana Health Sciences (USNA) shares fell about 30% after its Aug. 4 Q2 results missed expectations and guidance disappointed. The company reported non-GAAP EPS of $0.07 on about $223M sales, with sales and profit below analyst averages. It also took a $29M goodwill impairment on Hiya, cut 2024 guidance to an $11M loss and lowered sales to $910M from $925M-$1B.

yahoo.com6 min
AUG 4
$USNAHigh

USANA HEALTH SCIENCES INC (USNA): Results of Operations and Financial Condition

USANA HEALTH SCIENCES INC (USNA) filed an SEC Form 8-K — Results of Operations and Financial Condition. USANA Health Sciences Reports Second Quarter 2026 Results Company Continues Evolution to a Diversified, Omnichannel Health and Wellness Business SALT LAKE CITY, August 4, 2026 (BUSINESS WIRE)—USANA Health Sciences, Inc. (NYSE: USNA) today announced financial results for its fisca

SEC EDGAR 8-K6 min